Market Access Impact: Multiple Sclerosis (US) 2019

What are the market access obstacles that are shaping the US multiple sclerosis market and which brands are winning out?

• How are market barriers affecting multiple sclerosis drug prescribing?
• How do market barriers affect the market share of leading brands?
• What specific market access barriers are challenging each brand?
• Which brands gain and lose the most market share due to market barriers?

High cost, no formulary listing and stock availability are just some of the barriers that can negatively influence prescribing volumes and exert downward pressure on profitability. What market access barriers are influencing physicians’ therapy choices and how is this determining market share?

This and other key questions are answered in this insightful July 2019 analysis of 13 leading multiple sclerosis brands. Based on the results of an in-depth survey of 100 US-based neurologists, Market Access Impact (US): Multiple Sclerosis identifies the market access barriers that are shaping the competitive landscape for leading multiple sclerosis brands in the US and provides clear pointers for management action.

Evaluating leading companies in the US multiple sclerosis sector

• Bayer
• Biogen
• EMD Serono
• Novartis
• Roche
• Sanofi
• Sanofi/Genzyme
• Teva

Leading brands covered in this report

• Aubagio (teriflunomide; Sanofi)
• Avonex (interferon beta-1a; Biogen)
• Betaseron (interferon beta-1b; Bayer)
• Copaxone (glatiramer acetate; Teva)
• Gilenya (fingolimod; Novartis)
• Lemtrada (alemtuzumab; Sanofi/Genzyme)
• Mavenclad (cladribine; EMD Serono)
• Mayzent (siponimod, Novartis)
• Ocrevus (ocrelizumab; Roche)
• Plegridy (peginterferon beta-1a; Biogen)
• Rebif (interferon beta-1a; EMD Serono)
• Tecfidera (dimethyl fumarate; Biogen)
• Tysabri (natalizumab; Biogen)

Answering important market access questions

• What underpins the physicians’ prescribing of Copaxone, Tecfidera and Gilenya?
• What is the overall impact of market barriers on prescribing?
• Not available on formulary? Not recommended in guidelines? Limited availability? What market access obstacles are impacting Plegridy, Rebif and Tysabri?
• How many market barriers are impacting Mavenclad, Lemtrada and Ocrevus?
• How are market access issues impacting the market shares of Aubagio, Avonex and Betaseron and which competitor brands are benefitting?

Market access barriers examined in this survey

• Not available on formulary
• Too expensive
• Not recommended by guidelines
• Limited availability
• Patients prefer other medications
• Only recommended for certain patient types
• Is not reimbursable

Exclusive to FirstView, Market Access Impact surveys reveal the barriers that influence prescribing, identify the brands that win or lose market share, and highlight the
brand-specific market access challenges that management must overcome

The experience of the physicians surveyed

This detailed analysis is based on a survey of 100 US neurologists with a wealth of experience treating multiple sclerosis. On average they:

• Saw 58 patients the month preceding the survey
• Have 18 years in practice
• Have prescribed at least one of the brands assessed

This report gives you...

• Practical data to understand how market barriers impact the prescribing decisions neurologists treating multiple sclerosis make
• 33 clear, easy-to-read, charts that provide at-a-glance understanding of the survey findings
• Actionable and detailed information identifying specific areas where medical access teams can improve brand share

Why FirstView has an edge in pharmaceutical market research

FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.

Other MULTIPLE SCLEROSIS reports available

Market Access Impact (Europe): Multiple Sclerosis

Medical Affairs Reputations (US): Multiple Sclerosis

Medical Affairs Reputations (Europe): Multiple Sclerosis

NPS+ US: Multiple Sclerosis

NPS+ Europe: Multiple Sclerosis

Multiple Sclerosis: KOL Insight

To learn about our cost effective Multiple Sclerosis intelligence package of all reports, please contact us at info@fwreports.com